Skip to main content
Quest Diagnostics Home

COVID-19, flu, and RSV combination testing

Know more, sooner, with COVID-19 and respiratory molecular combination testing

SARS-CoV-2 (COVID-19), influenza, RSV, and other respiratory viruses can present with similar symptoms such as fever, cough, and shortness of breath. For at-risk groups1-3 or patients with a more acute illness, an expedited diagnosis is crucial, so treatment can be initiated while it’s most effective.1-3 That’s why it’s important to test for each of these illnesses at the same time.

Testing that supports a faster diagnosis

When a patient presents in-office with respiratory illness symptoms, send the specimen directly to Quest for the convenience of combination testing. Our SARS-CoV-2 (COVID-19) and respiratory molecular combination tests use a single specimen to test for common respiratory viruses, providing timely results to help you develop an appropriate care plan.

Why choose SARS-CoV-2 (COVID-19) and respiratory molecular combination tests for your patients

Distinguishes between SARS-CoV-2 (COVID-19), influenza A and B, RSV, and other respiratory pathogens with just 1 swab

Eliminates the need for multiple tests or patient visits—helping to speed up the time to a diagnosis

Reduces diagnostic uncertainty and can help guide early treatment management decisions4

Highly sensitive and specific, nucleic acid amplification tests (also known as molecular tests) capable of detecting 1 or more viruses are the diagnostic “gold standard”4

Combination testing options from Quest Diagnostics

Molecular offerings and panels for respiratory pathogen testing
SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT
SARS-CoV-2 RNA (COVID-19), Influenza A/B and RSV RNA, Qualitative NAAT
SARS-CoV-2 RNA (COVID-19) and Respiratory Viral Panel, Qualitative NAAT
SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT
Molecular respiratory pathogen tests and panels (non-COVID)
Influenza A and B and RSV RNA, Qualitative, Real-Time RT-PCR
Respiratory Viral Panel, PCR
Respiratory Pathogen Panel

Other respiratory testing options

Molecular tests for COVID-19 and other respiratory pathogens
SARS-CoV-2 RNA (COVID-19), Qualitative NAAT
Influenza A and B RNA, Qualitative Real-Time PCR
Influenza A and B Virus with Subtyping, Real-Time PCR
Respiratory Syncytial Virus (RSV) RNA, Qualitative Real-Time PCR
Adenovirus DNA, Qualitative, Real-Time PCR
Rhinovirus RNA, Real-Time PCR
Enterovirus RNA, Qualitative, Real-Time PCR
Human Metapneumovirus RNA, Qualitative, Real-Time PCR
Parainfluenza Virus (Types 1, 2, 3 and 4) RNA, Qualitative, Real-Time PCR
Chlamydophila pneumoniae, DNA, Qualitative, Real-Time PCR
Mycoplasma pneumoniae DNA, Qualitative, Real-Time PCR
Panel components may be ordered separately.

PSC testing availability

SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT combination test is now available for collection at Quest Patient Service Centers (PSCs) for patients with mild symptoms.
Find a Quest PSC near you
39992-50-50.jpg

COVID-19 testing statements

  • The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
  • All tests have been authorized by FDA under EUAs for use by authorized laboratories;
  • The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
  • The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses, pathogens; and,
  • All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.


References

  1. CDC. Factors that affect your risk of getting very sick from COVID-19. Updated October 19, 2022. Accessed October 25, 2022. https://www.cdc.gov/coronavirus/2019-ncov/your-health/risks-getting-very-sick.html
  2. CDC. Flu treatment. Updated October 11, 2022. Accessed October 25, 2022. https://www.cdc.gov/flu/treatment/index.html
  3. CDC. RSV. Updated December 18, 2020. Accessed October 20, 2022. https://www.cdc.gov/rsv/index.html
  4. Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA’s diagnostics committee. Clin Infect Dis. 2020;71(10):2744-2751. doi:10.1093/cid/ciaa508

Questions?

For more information on our combination testing solutions, or to set up a Quest account, connect with a Quest representative.

Contact us

COVID-19

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.